Napoleon Perdis
This article was originally published in The Rose Sheet
Executive Summary
Australian beauty firm will enter the U.S. via electronic retailer HSN, the company announces. Beginning in August, Napoleon Perdis will reach 89 mil. households in the U.S. with demonstrations of the makeup artist's techniques and showcasing of the makeup collections. "Interactive retail is where the world is at," brand founder and CEO Napoleon Perdis says in a statement. "I am excited to bring out the celebrity in the viewer and take red carpet and celebrity to reality through makeup tips and techniques that are simple and effective." The brand launched in the U.S. in 2005 and is currently sold at four Napoleon Perdis concept stores and Saks Fifth Avenue, among other doors...
You may also be interested in...
Marketing In Brief
Hollywood Lips: New Hollywood Lips Plumping Balm mixes "science with seduction and superstars," according to founder and creator Bret Boreman. Boreman, an L.A.-based makeup artist, launched the line in April at Hollywood boutiques such as Kitson. The line comprises three Plumping Balms - in coconut, tangerine and passion fruit - that rely on shea butter and safflower oil, among other ingredients, to "plump and perfect" lips. The collection also features three lip treatments including Sweet Sugar Scrub, an orange-flavored lip exfoliant, and two moisturizers - Hydrating Night Balm, and Soothing Day Relief - to prep, heal and repair lips prior to plumping. The items are available for individual sale - the balms for $9.95, the scrub for $7 and the moisturizers for $8 - at select boutiques and are available in two- and three-item sets online at 1www.hollywoodlipsonline.com...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.